Raúl Arcega Revilla

We don’t have enough information about this author to calculate their statistics. If you think this is an error let us know.
Learn More
Background: Delayed-release dimethyl fumarate (DMF), indicated for the treatment of patients with relapsingremitting multiple sclerosis (MS), is a disease-modifying therapy with potential immunomodulatory and neuroprotective effects. In clinical trials,DMFwasassociatedwith reduced white blood cell and absolute lymphocyte counts. CurrentUSprescribing(More)
  • 1